clinical trial · NCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ovarian CancerBreast CancerEndometrial CancerBiliary Tract CancerNon-Small Cell Lung CancerAdvanced or Metastatic Solid TumorsLNCB74
brief summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
started
Jan 7, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Dec 16, 2025
official title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol